Safety of heparin bridging therapy for transrectal ultrasound-guided prostate biopsy in patients requiring temporary discontinuation of antithrombotic agents

SpringerPlus

Table 2 Uni- and multivariate logistic analysis of risk factors for complications

	Risk factors	Any complications			Bleeding-related events
	Risk factors	P value	HR	95% CI	P value	HR	95% CI
Univariate
Age	>70 years	0.023	1.57	1.06–2.32	0.004	2.14	1.27–3.61
Diabetes	Positive	0.004	2.09	1.26–3.44	0.052	1.91	0.99–3.67
Hypertension	Positive	0.883	1.03	0.69–1.53	0.802	0.94	0.55–1.58
PSA	>7.8 ng/mL	0.641	0.91	0.62–1.34	0.454	0.82	0.50–1.37
Prostate cancer	Positive	0.641	0.92	0.63–1.33	0.859	0.96	0.59–1.55
Number of biopsy cores	>10 cores	0.063	1.48	0.98–2.23	0.521	1.20	0.69–2.08
Use of oral antithrombotic agents	Positive	0.025	1.62	1.06–2.47	0.425	1.26	0.71–2.23
Number of oral antithrombotic agents	2 or more	0.043	1.38	1.01–1.90	0.281	1.26	0.83–1.92
Use of warfarin	Positive	0.679	1.19	0.53–2.65	0.745	1.19	0.42–3.37
Heparin-bridging	Positive	0.000	5.99	2.61–13.8	0.000	7.91	3.20–19.6
CHADS2 score	2 or higher	0.005	2.30	1.29–4.08	0.003	2.83	1.42–5.61
Multivariate
Age	>70 years	0.108	1.39	0.93–2.09	0.015	1.96	1.14–3.36
Diabetes	Positive	0.023	1.99	1.10–3.59	0.243	1.60	0.73–3.52
Number of biopsy cores	>10 cores	0.025	1.62	1.06–2.47	0.371	1.29	0.74–2.27
Use of oral antithrombotic agents	Positive	0.473	1.19	0.74–1.92	0.280	0.68	0.33–1.38
Heparin-bridging	Positive	0.002	4.78	1.77–13.0	0.001	7.52	2.29–24.8
CHADS2 score	2 or higher	0.912	0.96	0.44–2.06	0.655	1.25	0.47–3.31